MODULE 1: Multiple Myeloma (MM)

• Clinical and biological factors affecting the selection of up-front therapy for patients with MM
• Long-term findings with daratumumab-containing regimens for newly diagnosed MM; role for transplant-eligible and ineligible patients
• Published data with novel daratumumab-based quadruplet regimens for transplant-eligible patients with newly diagnosed MM
• Similarities and differences between daratumumab and isatuximab
• Key findings from the Phase III GMMG HD7 trial comparing isatuximab with RVd to RVd alone for transplant-eligible patients with newly diagnosed MM
• Ongoing Phase III studies of isatuximab as a part of induction therapy for transplant-eligible and ineligible patients
• Available data with and current role of minimal residual disease assessment in therapeutic decision-making
• Optimal maintenance approach for transplant-eligible and ineligible patients
• Results from Phase III trials evaluating isatuximab-based combination regimens for relapsed/refractory (R/R) MM
• Key results from the Phase III BOSTON trial leading to the FDA approval of selinexor in combination with bortezomib/dexamethasone for R/R MM; available data with other selinexor-based combinations
• Structural makeup and manufacturing of available B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell platforms
• Efficacy and safety findings from the KarMMa (idecabtagene vicleucel) and CARTITUDE-1 (ciltacabtagene autoleucel) trials for R/R MM
• Available and emerging data with and ongoing studies of BCMA-targeted CAR T-cell therapies in earlier lines of treatment
• Similarities and differences in the cellular targets and mechanisms of action of bispecific antibodies in MM
• Activity and responses observed with available (teclistamab) and investigational (elranatamab, linvoseltamab, ABBV-383) BCMA-targeted bispecific antibodies in R/R MM
• Biological rationale for and available data with non-BCMA-targeted bispecific antibodies (eg, talquetamab, cevostamab, forimtamig); FDA breakthrough therapy designation for talquetamab
• Spectrum, incidence and severity of toxicities, including cytokine release syndrome and neurotoxicity, with bispecific antibodies in patients with MM; mitigation and management protocols
• Published data with and current role of venetoclax-based therapy for patients with MM and t(11;14) or Bcl-2 overexpression
• Other promising novel strategies in clinical development for patients with MM

MODULE 2: Non-Hodgkin and Hodgkin Lymphoma

• Key findings from the Phase III POLARIX study comparing polatuzumab vedotin in combination with R-CHP to R-CHOP for untreated diffuse large B-cell lymphoma (DLBCL); recent FDA approval of this regimen and incorporation into clinical practice
• Available data with and ongoing and planned evaluation of other novel agents for DLBCL in the first-line setting
• Factors in the selection and sequencing of available treatments for R/R DLBCL
• Published research findings with polatuzumab vedotin and bendamustine/rituximab for R/R DLBCL
• Key clinical trial data with tafasitamab/lenalidomide and loncastuximab tesirine for R/R DLBCL
• Major efficacy and safety data with selinexor for patients with R/R DLBCL
• Available results from Phase III studies evaluating CAR T-cell therapy as second-line treatment for DLBCL; FDA approval of axicabtagene ciloleucel and lisocabtagene maraleucel in this setting
• Available data with and ongoing and planned evaluation of novel bispecific antibodies (eg, epcoritamab, glofitamab, mosunetuzumab, odronextamab) targeting CD20 and CD3 in DLBCL
• Integration of obinutuzumab into current treatment for follicular lymphoma (FL); final analysis of the Phase III GALLIUM study
• Long-term clinical trial findings with lenalidomide/rituximab for treatment-naïve and R/R FL
• Key findings from the Phase III CHRONOS-3 trial evaluating copanlisib with rituximab for R/R FL; current role in clinical practice
• Published findings with mosunetuzumab for R/R FL; recent FDA approval and optimal incorporation opposite other treatment options
• Available research with other CD20 x CD3 bispecific antibodies under development for FL, such as glofitamab, epcoritamab and odronextamab
• Long-term follow-up from the Phase III ECHELON-1 trial; selection of patients with advanced classical Hodgkin lymphoma (HL) for first-line brentuximab vedotin (BV) with doxorubicin/vinblastine/dacarbazine
• Early findings with BV-based therapy for early-stage, unfavorable-risk HL
• Available data with and current role of BV for older patients with newly diagnosed advanced HL
• Potential role of BV alone or with immune checkpoint inhibition as a bridge to transplant for patients experiencing disease progression on up-front treatment
• Research database supporting the use of Bruton tyrosine kinase (BTK) inhibitors for R/R mantle cell lymphoma (MCL); recent voluntary withdrawal of ibrutinib for this disease and implications for practice
• Pharmacologic similarities and differences between the noncovalent BTK inhibitor pirtobrutinib and covalent BTK inhibitors; implications for efficacy and tolerability
• Key findings from the Phase I/II BRUIN study leading to the FDA approval of pirtobrutinib for R/R MCL
• Available data with, current role of and ongoing trials assessing venetoclax alone or with other agents for MCL

MODULE 3: Chronic Lymphocytic Leukemia (CLL)

• Clinical, biological and practical factors in the selection of first-line treatment for CLL requiring active therapy
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for treatment-naïve CLL
• Implications for clinical decision-making of published studies comparing acalabrutinib and zanubrutinib, respectively, to ibrutinib for previously treated CLL
• Outcomes observed with venetoclax-based up-front regimens for older or unfit and fit patients with treatment-naïve CLL
• Frequency of tumor lysis syndrome and other adverse events with venetoclax therapy in CLL clinical trials; recommended protocols for monitoring, prevention and management
• Current and future role of minimal residual disease assessment in clinical decision-making
• Design, eligibility criteria and major efficacy and safety findings from the Phase III GLOW trial evaluating ibrutinib/venetoclax versus chlorambucil/obinutuzumab as first-line treatment for CLL
• Outcomes reported in available data sets investigating acalabrutinib or zanubrutinib in combination with venetoclax, with or without an anti-CD20 antibody
• Long-term follow-up from Phase III trials evaluating BTK inhibitors and venetoclax for R/R CLL
• Published data sets and ongoing studies exploring the role of rechallenge with an agent or class of agents received in a prior line of therapy
• Updated results among patients with R/R CLL in the BRUIN study of pirtobrutinib; potential clinical application
• Biological rationale for the investigation of CD19-directed CAR T-cell therapy for R/R CLL; key findings from the TRANSCEND CLL 004 trial